We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients...
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -6.33802816901 | 1.42 | 1.47 | 1.28 | 123571 | 1.37286914 | CS |
| 4 | 0.03 | 2.30769230769 | 1.3 | 1.47 | 1.28 | 181572 | 1.34308306 | CS |
| 12 | -0.1 | -6.99300699301 | 1.43 | 1.65 | 1.22 | 261715 | 1.4057036 | CS |
| 26 | -0.31 | -18.9024390244 | 1.64 | 2.32 | 1.22 | 293779 | 1.47526234 | CS |
| 52 | -4.44 | -76.9497400347 | 5.77 | 7.38 | 1.02 | 221170 | 2.31086441 | CS |
| 156 | -17.85 | -93.0656934307 | 19.18 | 21.1816 | 1.02 | 161049 | 5.25956414 | CS |
| 260 | -21.07 | -94.0625 | 22.4 | 37.61 | 1.02 | 166556 | 6.60805969 | CS |
Monksdream
2 months ago
Monksdream
3 months ago
herbied47
7 months ago
herbied47
7 months ago
Tacostocks
7 months ago
Money hunt
7 months ago
Tacostocks
7 months ago
AJ Freely
10 months ago
Tartiaboy
1 year ago
TrendTrade2016
2 years ago
TrendTrade2016
2 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
